@FierceBiotech: Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck. More | Follow @FierceBiotech
@JohnCFierce: Report: Novartis reorganization quietly claims 3,000 jobs in just 4 months. News | Follow @JohnCFierce
@DamianFierce: Bayer looks to boost its R&D budget to $15.5B over the next three years. News | Follow @DamianFierce
@EmilyMFierce: Brain cell communication plays role in regulating tau in Alzheimer's. Story | Follow @EmilyMFierce
> GlaxoSmithKline's ($GSK) China bribery scandal cost CEO Andrew Witty up to $410,000 in potential bonus money. Story
> Mathew Martoma, the ex-SAC fund manager convicted of insider trading, is asking a judge to toss that verdict and grant him a new trial, arguing that prosecutors failed to prove he obtained secret information before selling off shares of Wyeth and Elan. Article
> Perrigo is handing over ELND005, a former Elan treatment for Alzheimer's disease, to Transition Therapeutics ($TTHI) for an undisclosed sum, also making a $15 million investment in the biotech. More
@FierceMedDev: Twisted fibers make low-cost artificial muscle to be used in robotics, prosthetics. Item | Follow @FierceMedDev
@MarkHFierce: VC options may have declined in the device and Dx worlds, but they're far from gone. See: Abingworth. Story | Follow @MarkHFierce
@MichaelGFierce: A tattoo to deliver a treatment for deadly sandfly-borne skin disease? It's a first. Item from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Only 15 percent of all ovarian cancers are detected in early stages--but nVision Medical plans to change all that. Article | Follow @EmilyWFierce
> HeartWare's heart pump revenue jumped in Q4, thanks to U.S. growth. News
> Illumina's prenatal blood test shows standout results in NEJM. More
> S. Korea is trying to decide whether the Galaxy S5 is a medical device. Story
Pharma News
@FiercePharma: Best-read FP story yesterday: Eliquis earns best safety score in its class in analysis of FDA adverse event reports. Piece | Follow @FiercePharma
@TracyStaton: J&J's high-stakes argument against a $1.2B Risperdal fine begins in Arkansas' top court. News | Follow @TracyStaton
@EricPFierce: Mylan earnings get shot in the arm from epinephrine shortage. More | Follow @EricPFierce
@CarlyHFierce: Bayer's 2013 earnings are out. Release: More. BloombergNews' take: Article | Follow @CarlyHFierce
> GSK trims Witty's bonus in face of China probe. Story
> Endo loss widens, R&D chief departs amid regulatory struggles. Article